The HCFC1R1 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of MCF-7 human breast adenocarcinoma cells, carrying targeted disruptions in the HCFC1R1 gene. This product provides a heterogeneous knockout pool for loss-of-function studies, bypassing clonal selection and enabling analysis of gene function in a near-native genomic background.
The MCF-7 host cell line is an estrogen receptor alpha (ER??)-positive, progesterone receptor-positive luminal A breast cancer model derived from a metastatic pleural effusion. These epithelial cells are dependent on estrogen for growth and are extensively used to study hormone signaling, endocrine therapy response, and resistance mechanisms. The knockout is generated in this well-defined background, maintaining the ER??-dependent context critical for examining estrogen receptor coactivator biology.
HCFC1R1 (HPIP) encodes a scaffold protein that directly interacts with ER?? and the coregulator PBX1, assembling transcriptional complexes that include SRC-1 and HCFC1. It enhances ER??-mediated activation of proliferative genes such as MYC and CCND1, with upstream stimulation by 17??-estradiol, heregulin, and EGF. This coactivator function feeds into the PI3K/AKT/mTOR pathway, promoting cell cycle progression. Knockout of HCFC1R1 disrupts this signaling node, reducing ER?? transactivation and attenuating downstream PI3K/AKT activity.
In MCF-7 cells, HCFC1R1 is a critical mediator of estrogen-driven proliferation and has been implicated in endocrine therapy resistance. Loss of HPIP provides a valuable system to dissect its role in ER?? signaling independently of other cofactors, and to examine how its absence affects pathway activation, cell growth, migration, and sensitivity to antiestrogens such as tamoxifen.
Applications include western blotting for HPIP and phospho-AKT, RT-qPCR for MYC and CCND1, MTT proliferation assays, Transwell migration studies, ERE luciferase reporter assays, co-immunoprecipitation of ER?? complexes, RNA-seq profiling, and tamoxifen sensitivity screens. The polyclonal knockout pool is well suited for functional genomics studies, drug screening targeting ER?? coactivators, and mechanistic investigations of breast cancer signaling. For more information, contact Ascent Research.
